SAR development of lysine-based irreversible inhibitors of transglutaminase 2 for huntington's disease

ACS Medicinal Chemistry Letters

Volumn 3, Issue 12, 2012, Pages 1024-1028

  Wityak, John ^a   Prime, Michael E ^b   Brookfield, Frederick A ^b   Courtney, Stephen M ^b   Erfan, Sayeh ^b   Johnsen, Siw ^b   Johnson, Peter D ^b   Li, Marie ^b   Marston, Richard W ^b   Reed, Laura ^b   Vaidya, Darshan ^b   Schaertl, Sabine ^c   Pedret Dunn, Anna ^b   Beconi, Maria ^a   MacDonald, Douglas ^a   Muñoz Sanjuan, Ignacio ^a   Dominguez, Celia ^a  

^a CHDI MANAGEMENT CHDI FOUNDATION   (United States)

^b EVOTEC UK LTD   (United Kingdom)

^c EVOTEC AG   (Germany)

Author keywords

acrylamides; celiac disease; in vitro ADME; plasma stability; polar surface area

Indexed keywords

ACRYLAMIDE; ENZYME INHIBITOR; PROTEIN GLUTAMINE GAMMA GLUTAMYLTRANSFERASE 2; PROTEIN GLUTAMINE GAMMA GLUTAMYLTRANSFERASE 2 INHIBITOR; UNCLASSIFIED DRUG;

ARTICLE; CELIAC DISEASE; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG METABOLISM; DRUG POTENCY; HUMAN; HUNTINGTON CHOREA; IN VITRO STUDY; NONHUMAN; PRIORITY JOURNAL; STRUCTURE ACTIVITY RELATION;

EID: 84871208434     PISSN: None     EISSN: 19485875     Source Type: Journal    
DOI: 10.1021/ml300241m     Document Type: Article

References (25)

1. Greenberg, C. S.; Birckbichler, R. H. Transglutaminases: Multifunctional cross-linking enzymes that stabilize tissues FASEB J. 1991, 5, 3071-3077
2. Im, M.-J.; Riek, P.; Graham, R. A novel guanine nucleotide-binding protein coupled to the α1-Adrenergic receptor J. Biol. Chem. 1990, 265, 18952-18960
3. Lai, T.-S.; Slaughter, T.; Peoples, K.; Hettasch, J.; Greenburg, C. Regulation of human tissue transglutaminase function by magnesium-nucleotide complexes J. Biol. Chem. 1998, 273, 1776-1781
4. Hasegawa, G.; Suwa, M.; Ichikawa, Y.; Ohtsuka, T.; Kumagai, S.; Kikuchi, M.; Sato, Y.; Saito, Y. A novel function of tissue-type transglutaminase: protein disulfide isomerase Biochem. J. 2003, 373, 793-803
5. Pinkas, D.; Strop, P.; Brunger, A.; Khosla, C. Transglutaminase 2 undergoes a large conformational change upon activation PLOS Biol. 2007, 5, 2788-2796
6. Liu, S.; Cerione, R. A.; Clardy, J. Structural basis for the guanine nucleotide-binding activity of tissue transglutaminase and its regulation of transamidation activity Proc. Natl. Acad. Sci. U.S.A. 2002, 99, 2743-2747
7. Stamnaes, J.; Pinkas, D. M.; Fleckenstein, B.; Khosla, C.; Sollid, L. M. Redox regulation of transglutaminase 2 activity J. Biol. Chem. 2010, 285, 25402-25409
8. Mastroberardino, P. G.; Farrace, M.; Viti, I.; Pavone, F.; Fimia, G.; Melino, G.; Kodolfo, C.; Piacentini, M. Tissue transglutaminase contributes to the formation of disulphide bridges in proteins of mitochondrial respiratory complexes Biochim. Biophys. Acta 2006, 1757, 1357-1365
9. Molberg, O.; McAdam, S.; Sollid, L. Role of tissue transglutaminase in celiac disease J. Pediatr. Gastroenterol. Nutr. 2000, 30, 232-240
10. Mangala, L.; Mehta, K. In Transglutaminases: The Family of Enzymes with Diverse Functions; Mehta, K.; Eckert, R., Eds.; Karger: Basel, 2005; pp 125-138.
11. Siegel, M.; Khosla, C. Transglutaminase 2 inhibitors and their therapeutic role in disease states Pharmacol. Ther. 2007, 115, 232-245
12. Jeitner, T.; Pinto, J.; Krasnikov, B.; Horswill, M.; Cooper, A. Transglutaminases and neurodegeneration J. Neurochem. 2009, 109, 160-166
13. Muñoz-Sanjuan, I.; Bates, G. P. The importance of integrating basic and clinical research toward the development of new therapies for Huntington's disease J. Clin. Invest. 2011, 121, 476-483
14. Cariello, L.; de Cristofaro, T.; Zanetti, L.; Cuomo, T.; Di Maio, L.; Campanella, G.; Rinaldi, S.; Zanetti, P.; Di Lauro, R.; Varrone, S. Transglutaminase activity is related to CAG repeat length in patients with Huntington's disease Hum. Genet. 1996, 98, 633-5
15. Mastroberardino, P. G.; Iannicola, C.; Nardacci, R.; Bernassola, F.; DeLaurenzi, V.; Melino, G.; Moreno, S.; Pavone, F.; Oliverio, S.; Fesus, L.; Piacentini, M. Tissue transglutaminase ablation reduces neuronal death and prolongs survival in a mouse model of Huntington's disease Cell Death Differ. 2002, 9, 873-880
16. Bailey, C.; Johnson, G. Tissue transglutaminase contributes to disease progression in the R6/2 Huntington's disease mouse model via aggregate-independent mechanisms J. Neurochem. 2005, 92, 83-92
17. Chun, W.; Lesort, M.; Tucholski, J.; Faber, P. W.; MacDonald, M. E.; Ross, C. A.; Johnson, G. V. W. Tissue transglutaminase selectively modifies proteins associated with truncated mutant huntingtin in intact cells Neurobiol. Dis. 2001, 8, 391-404
18. Ruan, Q.; Quintanilla, R. A.; Johnson, G. V. Type 2 transglutaminase differentially modulates striatal cell death in the presence of wild type or mutant huntingtin J. Neurochem. 2007, 102, 25-36
19. Kumar, A.; Kneynsberg, A.; Tucholski, J.; Perry, G.; van Groen, T.; Detloff, P. J.; Lesort, M. Tissue transglutaminase overexpression does not modify the disease phenotype of the R6/2 mouse model of Huntington's disease Exp. Neurol. 2012, 237, 78-89
20. Keillor, J. W.; Chabot, N.; Roy, I.; Mulani, A.; Leogane, O.; Pardin, C. Irreversible inhibitors of tissue transglutaminase. In Advances in Enzymology and Related Areas of Molecular Biology; Toone, E. J., Ed.; John Wiley & Sons, Inc.: New York, 2011; Vol. 78, pp 415-447.
21. Prime, M. E.; Andersen, O. A.; Barker, J. J.; Brooks, M. A.; Cheng, R. K. Y.; Toogood-Johnson, I.; Courtney, S. M.; Brookfield, F. A.; Yarnold, C. J.; Marston, R. W.; Johnson, P. D.; Johnsen, S. F.; Palfrey, J. J.; Vaidya, D.; Erfan, S.; Ichihara, O.; Felicetti, B.; Palan, S.; Pedret-Dunn, A.; Schaertl, S.; Sternberger, I.; Ebneth, A.; Scheel, A.; Winkler, D.; Toledo-Sherman, L.; Beconi, M.; Macdonald, D.; Muñoz-Sanjuan, I.; Dominguez, C.; Wityak, J. Discovery and SAR of potent and selective covalent inhibitors of transglutaminase 2 for Huntington's disease J. Med. Chem. 2012, 55, 1021-1046
22. Prime, M. E.; Brookfield, F. A.; Courtney, S. M.; Gaines, S.; Marston, R. W.; Ichihara, O.; Li, M.; Vaidya, D.; Williams, H.; Pedret-Dunn, A.; Reed, L.; Schaertl, S.; Toledo-Sherman, L.; Beconi, M.; Macdonald, D.; Muñoz-Sanjuan, I.; Dominguez, C.; Wityak, J. Irreversible 4-Aminopiperidine transglutaminase 2 inhibitors for Huntington's disease ACS Med. Chem. Lett. 2012, 3, 731-735
23. Marrano, C.; de Macédo, P.; Keillor, J. W. Evaluation of novel dipeptide-bound α,β-unsaturated amides and epoxides as irreversible inhibitors of guinea pig liver transglutaminase Bioorg. Med. Chem. 2001, 9, 1923-1928
24. Veber, D. F.; Johnson, S. R.; Cheng, H.-Y.; Smith, B. R.; Ward, K. W.; Kopple, K. D. Molecular properties that influence the oral bioavailability of drug candidates J. Med. Chem. 2002, 45, 2615-2623
25. MacFaul, P. A.; Morley, A. D.; Crawford, J. J. A simple in vitro assay for assessing the reactivity of nitrile containing compounds Bioorg. Med. Chem. Lett. 2009, 19, 1136-1138